Barclays Maintains Overweight on Abivax, Raises Price Target to $148

Barclays analyst Etzer Darout has maintained an Overweight rating on Abivax (NASDAQ: ABVX) and raised the price target from $142 to $148. This adjustment reflects a positive outlook on the company's performance.